|
|
Bioinformatics.org
|
![[?]](https://www.bioinformatics.org/images/icons/info.png)
|
|
Research
|
Online databases
Online analysis tools
Online education tools
|
|
Development
|
|
|
Forums
|
News & Commentary
Jobs Forum
(Career Center)
|
|
|
Latest announcements
|
|
March 19, 2025 (online event)
March 20-21, 2025 (in Florence, Italy)
http://conference.pixel-online.net/NPSE/callforpapers.php
The event brings together teachers, researchers, practitioners and project managers from all over the world to share findings, expertise and experience about innovative science teaching and learning methodologies.
Onsite participants are welcome in Florence for two full days of thought-provoking sessions, integrated by endless networking opportunities and social events.
Online participants can contribute with asynchronous or synchronous online presentations. The latter will be delivered on 19 March via the Conference Virtual Platform.
During the Conference:
- All accepted papers will be presented onsite and online.
- Questions and Answers sessions will follow each paper presentation.
- Poster presentation sessions will be held onsite and online.
- Networking opportunities will be organized.
IMPORTANT DATES
Abstracts submission deadline: October 9, 2024
Papers submission (possibility to extend): January 22, 2025
Conference day of the ONLINE EVENT: March 19, 2025
Conference days of the ONSITE EVENT IN FLORENCE: March 20-21, 2025
All accepted papers will be included in the Conference Proceedings e-book published with ISBN, ISSN and DOI codes. The publication will be sent to be reviewed for inclusion Web of Science and SCOPUS. The publication will also be included in Academia.edu and indexed in Google Scholar.
|
|
Creative Biolabs, a leading CRO, is proud to announce the opening of applications for its 2024 scholarship program. This initiative aims to provide financial assistance to students within the biotechnology industry, supporting their academic pursuits and research endeavors.
The Creative Biolabs Scholarship Program reflects the company's commitment to nurturing the next generation of biotech talent. As a renowned provider of biopharmaceutical development solutions, Creative Biolabs recognizes the importance of investing in the education and advancement of young scientists and researchers.
"We are excited to launch our 2024 scholarship program, which underscores our dedication to fostering innovation and excellence in the field of biotechnology," according to a scientist at Creative Biolabs. "Through this initiative, we aim to empower students to pursue their academic and professional aspirations, ultimately contributing to the advancement of the biotech industry."
The scholarship program opens to undergraduate, graduate, and doctoral students pursuing studies in science-related fields, with a focus on areas such as immunology, biochemistry, and molecular biology, which play a crucial role in the development of novel biopharmaceuticals and are key areas of focus for Creative Biolabs. Applicants will be evaluated based on academic merit, research achievements, leadership potential, and a personal statement outlining their career goals and aspirations in biotechnology.
"In addition to financial support, the recipients of the Creative Biolabs Scholarship have the chance to learn more about the exclusive resources and networking opportunities within the biotech community. This includes access to Creative Biolabs' cutting-edge technologies and platforms, such as high-throughput hybridoma generation, B cell sorting, and de novo antibody sequencing." The scientist elaborated.
High-Throughput Hybridoma Generation:
One of the key technologies offered by Creative Biolabs is the powerful Hyperdoma™, by far the most comprehensive and advanced hybridoma generation and screening platform, incorporating high-throughput screening systems like ClonePix 2, FMAT, and Celigo Image Cytometer. It fully takes advantage of the hybridoma machinery to sift out the best antibodies for any possible research, and meanwhile, its electrofusion and advanced screening approaches generate an expanded positive clone pool to largely maximize the possibility of producing the most viable clone, essential for the production of monoclonal antibodies. Utilizing this technology, researchers can significantly accelerate the process of antibody development and maximize their research efficiency.
De Novo Antibody Sequencing:
Another important solution is de novo antibody sequencing, which achieves 100% accuracy in interpreting antibody sequences and covers V, J, and C gene segments, the CDR3 region, fluorochrome mAbs and non-standard antibodies, and isobaric amino acids.
"Our scholarship recipients will have the opportunity to engage with industry-leading experts and learn more about state-of-the-art technologies like those above to further their research endeavors," said the scientist. "We believe that by investing in the education and development of talented students, we can drive innovation and advance the frontiers of biotechnology."
Interested students can find more information and apply for the scholarship program at https://www.creative-biolabs.com/scholarship-program.html.
ABOUT US
Creative Biolabs, specializing in biopharmaceutical development, offers a range of antibody discovery services. With a focus on nurturing talent, Creative Biolabs annually provides scholarships to biotech students, reflecting its dedication to education and innovation.
|
As a leading supplier of a wide range of biological products including recombinant proteins, native proteins, cell/tissue lysates, etc. and a high-quality custom service provider specializing in academic research, diagnostic and therapeutic applications as well as industry requirements, Creative BioMart always strives to support young and ambitious talents in our field.
To further support their research and higher education in the biomedical and science fields, Creative BioMart is proud to announce the 2024 Scholarship Program, which will award $1,000 to an outstanding college student.
Thanks for your interest in the 2024 Creative BioMart Scholarship Program!
REQUIREMENTS
The Creative BioMart scholarship is open on a global basis. To be eligible to receive a scholarship, you must meet the following requirements:
- Enrolled as an undergraduate, graduate or Ph.D. student at an accredited college, university or research Institute.
- Major in Biology, Biochemistry, Molecular Biology, Biotechnology or a related major.
- Can provide proof of a good average grade with at least a B (GPA 3.0/4.0).
EVALUATION CRITERIA
The Creative BioMart selection committee will review each application fairly and carefully according to the following criteria:
Academic ability: In addition to grade point average, your project, Bachelor's/Master's thesis, internship experience, or detailed learning plan will be considered.
Leadership skills: The ability to organize and positively influence others inside and outside of school.
Social concerns: Purposeful and meaningful participation in volunteer activities, community service or other public service activities.
|
BACKGROUND
This is a 3-year PhD position, that is part of a European Doctoral Network (DN) program entitled "Prostate cancer omics mediated intervention (PROMOTE)" involving 13 research centres from Germany, Greece, Austria, Portugal, and Spain.
The PhD position is hosted at Delta 4 GmbH, Vienna, Austria.
The PROMOTE Consortium / Background:
PROMOTE focuses on the multidisciplinary education of doctoral candidates (DCs) in -omics and artificial intelligence (AI) mediated intervention to improve the clinical management of Prostate Cancer (PCa). PCa is the second most common malignancy, affecting ~1.3 million men every year worldwide. Tragically, there is a treatment paradox, as ~45% of PCa patients experience slow-growing cancer and are unlikely to progress rapidly, while PCa is not curable at an advanced stage. Evidently, clinical management of PCa is not optimal, as patients who do not require treatment are over-treated, while for those where immediate actions are required, efficient treatment is still needed. To fill the above gaps, PROMOTE was formed to educate DCs in emerging -omics and AI technologies and deliver:
1. Novel non-invasive tools (based on biomarker- and AI- models) to guide intervention, and
2. More efficient treatment options for advanced PCa (particularly metastatic) driven by molecular characterization of the disease phenotypes.
PROMOTE brings together 13 leading centres from different disciplines, including 3 SMEs, 4 university hospitals with clinical laboratories, and 2 research institutes, and 4 universities, closely collaborating with a solid scientific background, as demonstrated by multiple publications.
PROMOTE research builds on:
1. Available biobanks and -omics datasets within the PROMOTE consortium, including >3000 urinary proteomics, >1100 imaging datasets paired with biopsy and pathology data, >350 paired RNA and proteomics urinary profiles, >100 tissue proteomics and ~300 phospho-, proteo-genomic and transcriptomics profiles from public repositories
2. Established software and analytical protocols on -omics data integration, AI feature extraction and integration, systems biology, pathway enrichment, drug repurposing and in vitro testing, and
3. Infrastructure to support hosting and training of DCs.
The PROMOTE partner hosting the PhD student:
Delta 4 GmbH is a Vienna-based TechBio company at the forefront of digital drug discovery and development. Delta4 leverages a proprietary computational analytics platform (Hyper-C), combined with biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects. Our R&D process allows a fast track to clinical stage testing; our methodological core is tailored toward precision to increase the probability of success. Our focus is the repositioning of existing drugs for novel indications.
With generating IP for such drug-disease combinations we establish a pipeline of clinically and economically attractive indications. Results of our lead program on the rare chronic kidney disease focal segmental glomerulosclerosis have been published recently (Transl Res. 2023 259:28-34 ; Kidney Int Rep. 2023 9(2):478-481). Previous computational data integration workflows have led to the identification of novel drug combinations in other tumor entities (Oncotarget. 2018 9(91):36379-36391; PLoS One. 2019 14(1):e0210859).
RESPONSIBILITIES
Objectives of the PhD:
The overall objective of this PhD-project in PROMOTE is to consolidate omics profiles in the context of prostate cancer to generate network-based molecular models for the disease. Network alignment methods shall be used to identify compounds that show beneficial interference between disease pathobiology and drug mechanism of action. A particular focus will be placed on compounds that affect target molecules involved in synthetic lethal interactions within the context of tumor progression. The potential of identified compounds and compound combinations targeting synthetic lethal interactions will be tested in combinations with researchers from the Medical University of Innsbruck.
Methods:
The PhD student will mostly work on data analysis and statistical analysis using R or Python. There will be some interaction with the wet laboratory (in-vitro compounds testing).
Expected Results:
- Meta analysis of omics data in the context of prostate cancer
- Generation of a network-based molecular model of prostate cancer
- Identification of compounds interfering with prostate cancer pathobiology
- Identification of drug combinations that address synthetic lethal interactions
REQUIREMENTS
- You hold a master's degree in bioinformatics/computational biology
- Fluent in a scripting language (R or Python) for data wrangling, explorative analysis and data visualization
- A solid understanding of cellular and molecular biology; knowledge of the hallmarks of cancer is a plus (Cell 2000 100:57-70; Cell 2011 144:P646-674)
- Experience with SQL, JSON, XML
- Statistical analysis of large biological datasets (e.g. Omics data)
- Experience with extracting data from key biological databases (NCBI, Ensembl, UniProt, GEO, ArrayExpress)
- Knowledge of key biological ontologies/vocabularies (Medical Subject Headings, Gene Ontology, Anatomical Therapeutic Chemical Classification, ...)
- Knowledge of graph theory and key graph measures
- Experience with biological network modelling and visualization (e.g. Cytoscape, igraph, ...)
Marie Skłodowska-Curie ITN rules:
- You must **NOT** have a **doctoral degree** at the date of your recruitment
- You must comply with the **mobility rule**: **not have resided** or carried out your main activity (work, studies, etc.) **in Austria** for more than 12 months in the 36 months immediately before the recruitment date.
The position includes 2 mandatory stays in partner laboratories to complete training:
1) Mosaiques Diagnostics GmbH: training proteomics data analysis.
2) Medical University Innsbruck: testing of drug combinations derived from the analysis of synthetic lethal interactions.
BENEFITS
- You will benefit from all Marie Skłodowska-Curie Action scheme advantages.
- Participation in web seminars (in English) of the collaborative network of the laboratory.
- Participation in yearly meetings organised by the PROMOTE consortium, as well as international and national congresses.
- You will work at a modern office in the beautiful 8th district of Vienna.
TERMS
3-year PhD position
LOCATION
Vienna / AUSTRIA
COMPENSATION
3.200 - 4.000 EUR brutto / month
HOW TO APPLY
Please submit your candidacy via Join (https://join.com/companies/delta4/11804151) including the following information:
- Your CV and motivation letter
- Your MSc transcript (diploma, courses, and grades)
- Two reference letters or contact details from your previous scientific supervisors
DEADLINE
August 20th, 2024
|
|
|
|
![[University of Birmingham]](https://www.bioinformatics.org/images/ack_banners/Birmingham-728x90.gif)
![[Patsnap]](https://www.bioinformatics.org/images/ack_banners/Patsnap-728x90.png)
